Related Experiment Video
Updated: Jun 10, 2026
05:31
Transradial Access Chemoembolization for Hepatocellular Carcinoma Patients
Published on: September 20, 2020
Have we fallen off target with concerns surrounding dual RAAS blockade?
Michael R Lattanzio1, Matthew R Weir
1Division of Nephrology, Department of Medicine, University of Maryland School of Medicine, Baltimore, Maryland 21201, USA.
Kidney International
|July 30, 2010
Summary
Misinterpretation of the ONTARGET trial data has raised concerns about dual renin-angiotensin-aldosterone system (RAAS) blockade for kidney disease. This analysis clarifies its appropriate use in specific patient groups, particularly those with proteinuric kidney disease.
Area of Science:
- Nephrology
- Cardiovascular Medicine
- Pharmacology
Background:
- The ONTARGET trial's results have been misinterpreted, leading to unwarranted concerns about dual renin-angiotensin-aldosterone system (RAAS) blockade efficacy and safety for renal outcomes.
- Concerns primarily stem from the study's specific cohort (non-proteinuric CKD patients) and insufficient statistical power for renal endpoints.
Purpose of the Study:
- To critically analyze the ONTARGET study's findings in the context of dual RAAS blockade.
- To provide evidence-based substantiation for the use of dual RAAS blockade in specific kidney disease populations.
Main Methods:
- Critical review of the ONTARGET trial data.
- Analysis of existing literature on dual RAAS blockade in various patient cohorts.
- Examination of different dual RAAS blockade combinations (ACE inhibitors, ARBs, MRAs, DRIs).
Main Results:
- Dual RAAS blockade demonstrates cardiac and renal protective effects in select populations, notably proteinuric chronic kidney disease (CKD) and congestive heart failure (CHF).
- The study population in ONTARGET (non-proteinuric CKD) was not adequately powered to assess renal outcomes.
- Responses to dual RAAS blockade may vary across different patient groups and drug combinations.
Conclusions:
- Misinterpretation of the ONTARGET trial should not preclude the use of dual RAAS blockade in appropriate patients.
- Dual RAAS blockade is supported by literature for select populations, including those with proteinuric kidney disease.
- Further research and careful patient selection are warranted for optimizing dual RAAS blockade strategies.
Related Concept Videos
01:25Antihypertensive Drugs: Direct Renin Inhibitors
The renin-angiotensin-aldosterone system (RAAS) is an intricate physiological pathway involving numerous enzymes and hormones, including renin, angiotensin-converting enzyme (ACE), angiotensin I and II, and aldosterone. Imbalances within this system increase the production of angiotensin II and aldosterone. Increased angiotensin II levels promote vasoconstriction and blood pressure elevation. Concurrently, higher aldosterone levels stimulate sodium and water reabsorption in the kidneys,...
01:25Antianginal Drugs: Calcium Channel Blockers and Ranolazine
Angina pectoris, a primary symptom of ischemic heart disease, requires careful pharmacological interventions. In this context, calcium channel blockers (CCBs) and ranolazine have emerged as crucial pharmacotherapeutic agents, providing deep insights into the complexities of angina management.
CCBs, a diverse class that includes dihydropyridines (nifedipine) and diphenylalkylamines (verapamil and diltiazem), exert their effect by blocking calcium channels in cardiac and smooth muscle cells. This...
CCBs, a diverse class that includes dihydropyridines (nifedipine) and diphenylalkylamines (verapamil and diltiazem), exert their effect by blocking calcium channels in cardiac and smooth muscle cells. This...
02:38The Ras Gene
The Ras-gene-encoded proteins are regulators of signaling pathways controlling cell proliferation, differentiation, or cell survival. The Ras-gene family in humans constitutes three primary members—the HRas, NRas, and KRas. These genes code for four functionally distinct yet closely related proteins—the HRas, NRas, KRas4A, and KRas4B. The involvement of mutant Ras genes in human cancer was first discovered in 1982 and is among the most common causes of human tumorigenesis.
Ras is a superfamily...
Ras is a superfamily...
01:25Rab Cascades
Rab GTPases act in a regulated cascade during membrane fusion, helping the lipid bilayers mix. The Rab family of proteins are active when bound to GTP, and inactive when bound to GDP. Hence, they act as guanine nucleotide-dependent molecular switches. Rab-GTP recognizes and binds to long or short-range tethering proteins to capture the target vesicle. These tethers coordinate with SNAREs on the vesicle and the target membrane to assemble the trans SNARE complex that locks the mixing bilayers.
01:29Neuromuscular Junction And Blockade
The site of chemical communication between a motor neuron and a muscle fiber is called the neuromuscular junction (NMJ). The end of the motor neuron at the NMJ divides into a cluster of synaptic end bulbs. The cytoplasm of these bulbs consists of synaptic vesicles enclosing acetylcholine molecules, the principal neurotransmitter released at the NMJ. The region opposite the synaptic bulb that ends in the muscle fiber is called the motor end plate, which has acetylcholine receptors. Within the...
01:26Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...